Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.

The primary endpoint at week 24 showed a highly significant reduction in gadolinium (Gd)-enhancing brain MRI lesions with ocrelizumab treatment vs placebo; the number of Gd-enhancing lesions was 89% ( p < 0.0001) lower in the 600 mg ocrelizumab group than in the placebo group, and 96% ( p < 0.0001) lower in the 2000 mg group [ 3 ].

also in 83,176 other papers

After 36 weeks of the assessed TFP, a weak trend toward increase in absolute EDSS scores was noted.

also in 834 other papers